Beta-Blockers vs ACE Inhibitors vs ARBs: Heart Failure Pharmacology
Three drug classes form the backbone of guideline-directed heart failure therapy. Here is exactly how beta-blockers, ACE inhibitors, and ARBs differ in mechanism, nursing monitoring, and NCLEX-priority assessments.
Learning Objectives
- ✓Distinguish beta-blockers, ACE inhibitors, and ARBs by mechanism and indication.
- ✓Identify the key labs and vital signs to monitor with each class.
- ✓Recognize ACE-inhibitor cough vs angioedema and the conversion to ARB therapy.
1. Direct Answer: Three Mechanisms, One Goal
Heart failure with reduced ejection fraction (HFrEF) is treated with GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT) — beta-blockers, ACE inhibitors or ARBs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — all of which improve survival. BETA-BLOCKERS (carvedilol, metoprolol succinate, bisoprolol) block beta-1 cardiac receptors to slow heart rate, reduce contractility, lower myocardial oxygen demand, and over months reverse pathologic remodeling. ACE INHIBITORS (lisinopril, enalapril, captopril) block conversion of angiotensin I to II, dropping vasoconstriction, aldosterone, and afterload while also raising bradykinin (which causes the classic dry cough). ARBs (losartan, valsartan, candesartan) block angiotensin II at the AT1 receptor — the same downstream effects without bradykinin elevation, so no cough. NCLEX priorities differ for each: beta-blockers focus on heart rate and BP at administration; ACE inhibitors and ARBs focus on K+, creatinine, and angioedema.
Key Points
- •Beta-blockers: block beta-1, reduce HR/contractility, reverse remodeling.
- •ACE inhibitors: block A-I → A-II, reduce afterload + aldosterone; cause cough.
- •ARBs: block angiotensin II receptor; same effect without cough.
2. Beta-Blockers: Nursing Considerations
ONLY THREE BETA-BLOCKERS are FDA-approved and guideline-recommended for HFrEF: carvedilol (alpha-1 and non-selective beta), metoprolol SUCCINATE (extended-release, beta-1 selective), and bisoprolol (beta-1 selective). Metoprolol TARTRATE (immediate-release) is NOT a HF agent — students confuse the two routinely. Initiate at LOW dose and titrate slowly over weeks; rapid initiation in decompensated HF can worsen failure. HOLD parameters: SBP < 90 or HR < 50, or new symptoms of decompensation. Side effects: bradycardia, hypotension, fatigue, depression, masked hypoglycemia (in diabetes — patients may not feel the tachycardia warning), bronchospasm with non-selective agents in asthma. Patient teaching: never stop abruptly (rebound tachycardia, MI risk), monitor pulse at home, get up slowly from sitting.
Key Points
- •Only carvedilol, metoprolol SUCCINATE, and bisoprolol are HF beta-blockers.
- •Hold for HR < 50 or SBP < 90 unless ordered otherwise.
- •Never stop abruptly — taper over 1-2 weeks.
3. ACE Inhibitors: Nursing Considerations
First-line for HFrEF unless contraindicated. Watch FIRST-DOSE HYPOTENSION — give the first dose with the patient supine, monitor BP every 15 minutes for the first hour. MONITOR LABS: serum potassium (ACE inhibitors raise K+ by decreasing aldosterone), serum creatinine (may rise 20-30% as efferent arteriole vasoconstriction is removed — generally acceptable), BUN. CONTRAINDICATIONS: pregnancy (teratogenic, BLACK BOX), bilateral renal artery stenosis (precipitous renal failure), history of angioedema. SIDE EFFECTS: dry persistent cough (10-20% from bradykinin), hyperkalemia, hypotension, acute kidney injury, ANGIOEDEMA (swelling of lips, tongue, throat — emergency, discontinue immediately and never re-challenge). Patient teaching: monitor for cough/swelling, avoid potassium supplements and salt substitutes (which contain KCl), report symptoms of dehydration.
Key Points
- •First-dose hypotension — monitor BP every 15 min for first hour.
- •Watch K+, creatinine; 20-30% creatinine rise often acceptable.
- •Angioedema is emergent — never re-challenge with another ACE inhibitor.
4. ARBs: When ACE Doesn't Work
ARBs are second-line for patients who cannot tolerate ACE inhibitors due to COUGH (the most common reason for switching) or angioedema (still a risk on ARBs but much lower). Mechanism: block angiotensin II at the AT1 receptor without affecting bradykinin metabolism, so no cough. EQUAL EFFICACY to ACE inhibitors for HFrEF, blood pressure control, and renal protection. Monitoring is identical to ACE inhibitors: K+, creatinine, BP. SAME contraindications: pregnancy, bilateral RAS, history of angioedema (though risk is much lower). Patient teaching: still avoid K+ supplements and salt substitutes; report symptoms suggesting angioedema. ARBs are typically the agent of choice when angioedema or refractory cough has eliminated ACE inhibitors as an option.
Key Points
- •ARBs avoid the bradykinin cough by blocking the receptor downstream.
- •Equal HF efficacy to ACE inhibitors at equivalent doses.
- •Same monitoring and contraindications (cautious in prior angioedema).
5. ARNI and Combination Therapy
Sacubitril/valsartan (Entresto) combines an ARB (valsartan) with a NEPRILYSIN INHIBITOR (sacubitril) that prevents breakdown of natriuretic peptides — improving vasodilation, natriuresis, and HF outcomes. Switch from ACE to ARNI requires a 36-hour washout period to avoid additive angioedema risk. ARNI replaces ACE/ARB in current guidelines as the preferred RAAS-targeting agent in HFrEF when affordable. Combining ACE inhibitor + ARB is contraindicated (additive hyperkalemia, renal injury, and angioedema without benefit). The fourth pillar of guideline-directed HF therapy — SGLT2 inhibitors (dapagliflozin, empagliflozin) — provides additional mortality benefit regardless of diabetes status, completing the modern regimen of beta-blocker + ACEi/ARB/ARNI + MRA + SGLT2i.
Key Points
- •Sacubitril/valsartan (Entresto) is ARB + neprilysin inhibitor; preferred over ACE/ARB alone.
- •Switch ACE → ARNI requires 36-hour washout.
- •Never combine ACE + ARB; SGLT2 inhibitors are the modern fourth pillar.
6. Patient Education Pearls
Beta-blockers: take with food to reduce dizziness; do not stop abruptly; carvedilol can cause orthostatic hypotension at initial doses — get up slowly. ACE inhibitors: dry cough is common, not dangerous, may take weeks to resolve after switching; SWELLING OF LIPS OR TONGUE is emergency, call 911 immediately; avoid salt substitutes (contain KCl) and OTC potassium supplements; report dizziness, fatigue, or change in urination. ARBs: same teaching minus the cough. ALL THREE: never take with NSAIDs chronically (NSAIDs raise BP, blunt response, and add renal toxicity); monitor weight daily (weight gain > 2 lb/day or 5 lb/week signals fluid retention requiring follow-up); take medications same time every day to maintain blood levels.
Key Points
- •Beta-blockers: never stop abruptly; take with food.
- •ACE inhibitors: cough is harmless but lip/tongue swelling is emergent.
- •All three: avoid chronic NSAIDs and OTC K+ supplements.
7. Using NurseIQ for HF Pharmacology
Photograph a med order or describe a patient scenario and NurseIQ identifies the drug class, lists nursing priorities (hold parameters, labs to check, patient teaching), and flags drug interactions and contraindications. The HF protocol generator walks through guideline-directed medical therapy initiation with rate-limiting considerations. This content is for educational purposes only and does not constitute medical advice.
Key Points
- •Drug-class identification with nursing priorities.
- •Hold parameters and lab monitoring summarized per drug.
- •Patient teaching prompts for each class.
High-Yield Facts
- ★Beta-blockers approved for HFrEF: carvedilol, metoprolol SUCCINATE, bisoprolol only.
- ★ACE inhibitors raise K+ and creatinine; 20-30% creatinine rise often acceptable.
- ★ACE inhibitor cough = bradykinin; switch to ARB resolves it.
- ★Angioedema is a class effect of ACE inhibitors; ARB risk is lower but real.
- ★Sacubitril/valsartan (Entresto) preferred over ACE/ARB alone in modern guidelines.
Practice Questions
1. A patient on lisinopril develops a persistent dry cough. The provider switches to losartan. What teaching does the nurse provide?
2. Why should metoprolol tartrate NOT be ordered for chronic HF?
3. Pre-administration vitals show HR 48 and BP 95/60. The patient is on carvedilol 12.5 mg BID. What does the nurse do?
FAQs
Common questions about this topic
Angiotensin II normally vasoconstricts the efferent arteriole of the glomerulus, maintaining filtration pressure. Blocking it removes that vasoconstriction and lowers GFR, raising serum creatinine. A 20-30% rise is expected and acceptable — even reassuring as evidence the drug is working at the kidney. Larger rises (>30-50%) warrant evaluation for bilateral renal artery stenosis or volume depletion. The drug usually need not be stopped at the lower thresholds; the kidneys reach a new steady state.
Both are guideline-approved HF beta-blockers, but they differ in receptor profile and dose-titration ease. Carvedilol blocks alpha-1 in addition to beta-1 and beta-2 — broader effect on afterload but more dizziness and slower titration. Metoprolol succinate is beta-1 selective — fewer non-cardiac side effects, simpler titration, but less effect on systemic vascular resistance. Studies show similar mortality benefit; choice depends on individual tolerance and provider preference.
No. Angioedema is a class effect, and rechallenge with any ACE inhibitor (including lisinopril, captopril, enalapril, ramipril) is contraindicated. ARBs can usually be substituted, with the patient warned that angioedema risk persists at a lower rate. For patients with severe history, an ARNI (sacubitril/valsartan) requires careful evaluation and may also be avoided. Hydralazine plus nitrate is an alternative HF regimen for these patients.
First-dose hypotension is common, especially in patients who are volume-depleted, on diuretics, or have high renin states. The initial vasodilation can be dramatic. Standard precautions: give the first dose with the patient supine, monitor BP every 15 minutes for the first hour, hold diuretics for 24-48 hours before initiation if possible, start at the lowest available dose, and counsel the patient to get up slowly for the next several days.
Yes. Describe a patient scenario or photograph a med list and NurseIQ identifies the drug classes, lists nursing priorities (hold parameters, labs to check, patient teaching), flags interactions, and walks through guideline-directed medical therapy initiation with rate-limiting considerations. This content is for educational purposes only and does not constitute medical advice.